3191 results for «741»

Filter By

3191 results

TEER in complex tricuspid regurgitation - LIVE case

14 Feb 2026 – From PCR Tokyo Valves 2026

A 79-year-old male with permanent AF, prior colorectal and prostate cancer, and a Mosaic bioprosthetic mitral valve implanted in 2016, presented with torrential tricuspid regurgitation and preserved LV function.

Three G5 clips were implanted: two anteroseptal (1 XTW and 1 XT) and one posteroseptal XTW.

LIVE Educational Case...

TEER in complex tricuspid regurgitation - LIVE case

Hot topics and evidence on structural interventions in 2025 and 2026

14 Feb 2026 – From PCR Tokyo Valves 2026

Delve into the emerging clinical evidence and key hot topics shaping transcatheter interventions for aortic, mitral, and tricuspid valve diseases anticipated to influence clinical practice in 2025 and 2026. This session reviews stroke prevention, valve interventions across the three valves, and integrates recent and upcoming data...

Hot topics and evidence on structural interventions in 2025 and 2026

Prevention and management of TAVI complications

14 Feb 2026 – From PCR Tokyo Valves 2026

This session addresses the prevention and management of major complications associated with transcatheter aortic valve implantation (TAVI). Attendees will gain a detailed understanding of mechanisms behind cerebral infarction, haemolysis, valve infolding, pacemaker implantation, and valve migration, along with expert strategies for recognition, decision-making, and bailout techniques...

Prevention and management of TAVI complications

Primary mitral TEER in small anatomy - LIVE case

15 Feb 2026 – From PCR Tokyo Valves 2026

An 89-year-old male with diabetes mellitus, hypertension, chronic kidney disease (eGFR: 46), and CAD with a history of NSTEMI and CTO of the RCA, presented with symptomatic primary mitral regurgitation (P1–P2 prolapse) and preserved LV function (56%).

One Pascal ACE device was implanted.

LIVE Educational Case from Nagoya...

Primary mitral TEER in small anatomy - LIVE case

Guidelines update

15 Feb 2026 – From PCR Tokyo Valves 2026

This session reviews the latest updates in the ESC/EACTS guidelines for structural heart disease, emphasizing their clinical implications and future trends. Participants will gain understanding of changes in aortic, mitral, and tricuspid valve recommendations, including new age cutoffs, asymptomatic disease management, and the evolving role of...

Guidelines update

Future devices and techniques for structural heart disease

15 Feb 2026 – From PCR Tokyo Valves 2026

This session surveys the future landscape of structural heart disease treatment, addressing current limitations in transcatheter valve technologies and presenting emerging devices and techniques for aortic, mitral, and tricuspid valves. Attendees will gain insights into innovations poised to transform therapeutic options for structural heart disease.

Future devices and techniques for structural heart disease

Supraflex Cruz RCT in high bleeding risk patients now published in Circulation

16 Oct 2024

5-year outcomes after transcatheter or surgical aortic valve replacement in low-risk patients with aortic stenosis (Evolut Low Risk)

01 Apr 2025

Yohei Ohno provides his takeaways from the results of the Evolut Low Risk trial which was presented by Michael J. Reardon during the ACC.25 in Chicago.

Yohei Ohno

Author

Yohei Ohno
5-year outcomes after transcatheter or surgical aortic valve replacement in low-risk patients with aortic stenosis (Evolut Low Risk)

TRIGISTRY: Benefit of isolated surgical valve repair or replacement for functional tricuspid regurgitation and long-term outcomes stratified by the TRI-SCORE

31 Aug 2024

Alex Sticchi provides his take on the TRIGISTRY study presented by Julien Dreyfus at the ESC Congress 2024 in London.

Simultaneous publication in European Heart Journal, ehae578

Alessandro Sticchi

Author

Alessandro Sticchi
Benefit of isolated surgical valve repair or replacement for functional TR and long-term outcomes

Transcatheter vs surgical aortic valve replacement in aortic stenosis patients at low surgical risk: 3-year outcomes from the Evolut Low Risk trial

05 Mar 2023

Luigi Biasco provides his take on the clinical trial presented by John K. Forrest from Yale University School of Medicine, New Haven, Connecticut, USA during the 2023 ACC/WCC annual congress held in New Orleans, Louisiana.

Luigi Biasco

Author

Luigi Biasco
Transcatheter versus surgical aortic valve replacement in aortic stenosis patients at low surgical risk: 3-year outcomes from the Evolut low risk Trial

TRI.fr trial - Multicentric randomised evaluation of the transcatheter edge-to-edge repair in the treatment of severe isolated secondary tricuspid regurgitation

31 Aug 2024

Alex Sticchi provides his take on the results of the TRI.FR trial presented by Erwan Donal at the ESC Congress 2024 in London.

Alessandro Sticchi

Author

Alessandro Sticchi
Tri.fr trial
Didn’t find what you were looking for?